Company Dashboard
Eli Lilly and Company
LLYNYSEEli Lilly is a global pharmaceutical company. Revenue is concentrated in cardiometabolic health, driven by Mounjaro and Zepbound (tirzepatide). Oncology, immunology, and neuroscience round out the portfolio.
Coverage window
44 quarters from Q1 '15 to Q4 '25
Calendar fiscal year (Dec 31)
LLY Stock Price
$935.58▼ $18.94 (1.98%)as of Apr 3, 2026, 1:46 AM
Mkt Cap
$837.36B
P/E Ratio
40.82
52-wk High
$1,133.95
52-wk Low
$623.78
Source: Yahoo Finance · End-of-day data · Hover or tap for detail
Quarterly views track the calendar-year reporting cadence. Annual views aggregate by calendar year. The Products section breaks down individual drug revenue within each therapeutic segment.
Latest Revenue
$19.3B
Q4 '25 (Dec 2025)
+42.6% vs Q4 '24
Gross Margin
82.5%
Q4 '25
+0.3pp vs Q4 '24
GLP-1 Revenue Mix
60.5%
$11.7B of revenue
Mounjaro $7.4B + Zepbound $4.3B
R&D as % of Revenue
19.7%
$3.8B in Q4 '25
-2.6pp vs Q4 '24
Revenue
Cardiometabolic health now accounts for 75% of total revenue.
Mounjaro and Zepbound (both tirzepatide) dominate the cardiometabolic segment. Cardiometabolic mix was 67% a year ago.
Quarterly revenue
Calendar-year fiscal quarters
Latest
Q4 '25 $19.3B
+42.6% YoY · Peak Q4 '25
Source: Eli Lilly Financial Workbooks · Hover, focus, or tap bars for detail · Q4 highlighted
Product Breakdown
Individual drug revenue by therapeutic segment.
Select a segment to view the full product-level revenue breakdown with quarterly and annual trends.
R&D
R&D spend has scaled with revenue while intensity has compressed.
Absolute R&D spending has grown consistently. As revenue accelerated through GLP-1 adoption, R&D intensity (R&D as a percentage of revenue) has declined from above 25% toward 20%.
R&D investment
Research & development expense with R&D intensity line
Latest
Q4 '25 $3.8B
19.7% of revenue
Source: Eli Lilly Financial Workbooks + SEC EDGAR
R&D intensity (line) measures research spending as a share of revenue — declining intensity alongside rising absolute spend signals improving operating leverage from scaled drug launches.
Profitability
Gross margins have expanded as GLP-1 revenue scales.
Gross margin has moved from the low 70s in 2015 toward the low 80s. Net income volatility reflects acquired in-process R&D charges, impairments, and tax items.
Quarterly gross margin
Gross profit (revenue x gross margin)
Latest
Q4 '25 $15.9B
+0.3pp YoY margin
Source: Eli Lilly Financial Workbooks · Q4 highlighted
Capital Allocation
Cash flow funds dividends, buybacks, and manufacturing capacity.
Operating cash flow breakdown by capital expenditures, shareholder returns (dividends + buybacks), and retained free cash flow. Cash flow data availability varies by quarter.
Cash flow allocation
Operating cash flow breakdown (Q1 only — SEC quarterly data)
Source: SEC EDGAR XBRL — Click categories to filter
Balance Sheet
Debt levels have risen alongside manufacturing investment.
Point-in-time snapshots of cash, total debt, and stockholders' equity. LLY has added debt to fund manufacturing capacity expansion for GLP-1 production.
Balance sheet snapshot
Cash, debt & equity (point-in-time)
Latest
Q3 '25 $76.2B
Cash + Debt + Equity
Source: SEC EDGAR XBRL + Eli Lilly Financial Workbooks · Click to toggle · Hover, focus, or tap bars for detail
Annual Summary
Calendar-year fiscal year basis. Partial years remain visible so the data cut is explicit.
| Year | Revenue | Net Income | R&D | Free Cash Flow | Shares (M) | Quarters |
|---|---|---|---|---|---|---|
| 2015 | $16.8B | $2.5B | $4.9B | — | 1,067 | 4/4 |
| 2016 | $18.1B | $2.4B | $5.1B | — | 1,063,075 | 4/4 |
| 2017 | $19.8B | $1.5B | $5.3B | — | 1,056,306 | 4/4 |
| 2018 | $21.4B | $2.1B | $5.3B | — | 1,049,839 | 4/4 |
| 2019 | $22.3B | $6.8B | $5.5B | — | 984,001 | 4/4 |
| 2020 | $24.5B | $5.5B | $6.1B | — | 912 | 4/4 |
| 2021 | $28.3B | $5.2B | $6.8B | — | 912 | 4/4 |
| 2022 | $28.5B | $6.2B | $7.2B | $2.2B | 905 | 4/4 |
| 2023 | $34.1B | $3.1B | $9.3B | $1.1B | 904 | 4/4 |
| 2024 | $45.0B | $10.6B | $11.0B | $0.2B | 903 | 4/4 |
| 2025 | $65.2B | $20.6B | $13.3B | $0.2B | 898 | 4/4 |
Employment
Headcount rising with the GLP-1 pipeline
Eli Lilly annual headcount
Full-time employees as reported in annual SEC filings
Source: SEC filings (10-K) via Financial Modeling Prep
Methodology & Sources
Revenue and product-level data sourced from Eli Lilly Financial Workbooks published quarterly at investor.lilly.com. Income statement and cash flow data supplemented from SEC EDGAR XBRL filings. All figures in millions USD unless noted. Eli Lilly's fiscal year is the calendar year (Jan–Dec). Historical segment names are mapped to the current 5-segment structure: “Endocrinology” (2015–2019) and “Diabetes” (2020–2023) are mapped to Cardiometabolic Health; “Cardiovascular” (2015–2018) is mapped to Other. Animal Health revenue (2015–2018) is excluded as it was spun off as Elanco Animal Health.